Filing Details
- Accession Number:
- 0001179110-15-006183
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-09 16:40:06
- Reporting Period:
- 2015-04-08
- Filing Date:
- 2015-04-09
- Accepted Time:
- 2015-04-09 16:40:06
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1600041 | Rutherford Paul Carter | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Evp Commercial Ops | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-04-08 | 795 | $80.65 | 46,234 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2015-04-08 | 205 | $80.65 | 46,439 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-04-08 | 1,000 | $100.00 | 45,439 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2015-04-08 | 795 | $0.00 | 795 | $80.65 |
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2015-04-08 | 205 | $0.00 | 205 | $80.65 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
32,845 | 2024-02-01 | No | 4 | M | Direct | |
32,640 | 2024-02-01 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.